Time for radioimmunotherapy: an overview to bring improvements in clinical practice
- 219 Downloads
Harnessing the patient’s own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical “checkpoints” that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient’s own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity. Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.
KeywordsAbscopal effect Radiotherapy Radioimmunotherapy Immunotherapy combinations Immunogenic neoplasms
Compliance with ethical standards
Conflict of interest
No potential conflicts of interest were disclosed.
This review article did not imply research involving humans or animals.
Informed consent was not required.
- 5.Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273–90.Google Scholar
- 17.Lu H, Ford E, Schwartz JL, Hewitt J, Hsu FJ, et al. Intratumoral G100 rescues radiation-induced T cell depletion and has synergistic anti-tumor effect with local irradiation in A20 lymphoma. Blood. 2016;128:4166.Google Scholar
- 24.Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.CrossRefGoogle Scholar
- 29.Van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AM, De Ruysscher D, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med. 2015;27(13):32.CrossRefGoogle Scholar
- 30.SJ Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.Google Scholar
- 37.Ishiyama H, Teh BS, Ren H, Chiang S, Tann A, Blanco AI, Paulino AC, Amato R, et al. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourin Cancer. 2012;10(3):196–8.CrossRefGoogle Scholar
- 39.Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, et al. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med. 2014;23(12):262.CrossRefGoogle Scholar
Head and Neck References